Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series

References

• Drack AV. Preventing blindness in premature infants. N Engl J Med 1998;338:1620–1621.
   PubMed Web of Science ®Google Scholar
• Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, Tung B. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991;98:1628–1640.
   PubMed Web of Science ®Google Scholar
• Hardy RJ, Good WV, Dobson V, Palmer EA, Phelps DL, Quintos M, Tung B; Early Treatment for Retinopathy of Prematurity Cooperative Group. Multicenter trial of early treatment for retinopathy of prematurity: study design. Control Clin Trials 2004;25:311–325.
   PubMedGoogle Scholar
• Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, Tung B; Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005;116:15–23.
   PubMed Web of Science ®Google Scholar
• Dani C, Reali MF, Bertini G, Martelli E, Pezzati M, Rubaltelli FF. The role of blood transfusions and iron intake on retinopathy of prematurity. Early Hum Dev 2001;62:57–63.
   PubMed Web of Science ®Google Scholar
• Dani C, Martelli E, Bertini G, Pezzati M, Rossetti M, Buonocore G, Paffetti P, Rubaltelli FF. Effect of blood transfusions on oxidative stress in preterm infants. Arch Dis Child Fetal Neonatal Ed 2004;89:F408–F411.
   PubMed Web of Science ®Google Scholar
• Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res 2004;14 Suppl A:S140–S144.
   PubMedGoogle Scholar
• Repka MX, Tung B, Good WV, Shapiro M, Capone A Jr., Baker JD, Barr CC, et al. Outcome of eyes developing retinal detachment during the early treatment for retinopathy of prematurity study (ETROP). Arch Ophthalmol 2006;124:24–30.
   PubMed Web of Science ®Google Scholar
• Gilbert WS, Quinn GE, Dobson V, Reynolds J, Hardy RJ, Palmer EA. Partial retinal detachment at 3 months after threshold retinopathy of prematurity. Long-term structural and functional outcome. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1996;114:1085–1091.
   PubMedGoogle Scholar
• Wu WC, Drenser KA, Lai M, Capone A, Trese MT. Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. Retina (Philadelphia, Pa) 2008;28:S75–S80.
   PubMed Web of Science ®Google Scholar
• Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007;10:133–140.
   PubMedGoogle Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603–615.
   PubMed Web of Science ®Google Scholar
• International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005;124:1669–1670.
   Google Scholar
• Ng EY, Lanigan B, O’Keefe M. Fundus fluorescein angiography in the screening for and management of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 2006;43:85–90.
   PubMed Web of Science ®Google Scholar
• Roohipoor R, Ghasemi H, Ghassemi F, Karkhaneh R, Riazi-Esfahani M, Nili-Ahmadabadi M. Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. Graefes Arch Clin Exp Ophthalmol 2011;249:1295–1301.
   PubMed Web of Science ®Google Scholar
• Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, Prieto I, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007;38:233–237.
   PubMedGoogle Scholar
• Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007;55:75–76.
   PubMedGoogle Scholar
• Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727–1730.
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, Johnson RA, Puliafito CA. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina (Philadelphia, Pa) 2008;28:S13–S18.
   PubMed Web of Science ®Google Scholar
• Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina (Philadelphia, Pa) 2008;28:S19–S25.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina (Philadelphia, Pa) 2008;28:831–838.
   PubMed Web of Science ®Google Scholar
• Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061–1063.
   PubMed Web of Science ®Google Scholar
• Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, Fujikado T. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008;92:1450–1455.
   PubMed Web of Science ®Google Scholar
• Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 2010;14:6–10.
   PubMed Web of Science ®Google Scholar
• Altinsoy HI, Mutlu FM, Güngör R, Sarici SU. Combination of laser photocoagulation and intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2010;:1–:5.
   PubMedGoogle Scholar
• Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 2010;248:1257–1262.
   PubMed Web of Science ®Google Scholar
• Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina (Philadelphia, Pa) 2010;30:S24–S31.
   PubMedGoogle Scholar
• Kychenthal A, Dorta P. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Retina (Philadelphia, Pa) 2010;30:S32–S36.
   PubMedGoogle Scholar
• Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther 2011;27:623–627.
   PubMed Web of Science ®Google Scholar
• Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Ku-saka S. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327–333.
   PubMed Web of Science ®Google Scholar